ERBB2 and non-small cell lung carcinoma: An additional phase II trial of trastuzumab ematansine with several cohorts across different disease types that specifically analyzed NSCLC patients (N = 18 patients) with HER2 mutations by NGS rather than overexpression by IHC found ORR was 44% (95% CI, 22% to 69%) and median PFS was 5 months [95% CI, 3 to 9 months] [60] (NCT02675829).